
GeneDx Holdings Corp.: updates and filings
Price
$45.46
November 20, 2026Market cap $1.3B
What Ploutos Investor adds for GeneDx
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 31% since Nov 9, 2026, when the 10-Q these figures come from was filed ($65.72 then, $45.46 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 3, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 18, 2026Officer or director change, Regulation FD disclosureForm8-K
- Nov 17, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Nov 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 11, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 3, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 3, 2026Results of operationsForm8-K
- Jul 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 21, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Jun 23, 2026Shareholder voteForm8-K
- Jun 16, 2026Officer or director change, Regulation FD disclosureForm8-K
- May 22, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 15, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 11, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operationsForm8-K
- Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 30, 2026Additional annual meeting materialFormDEFA14A
- Apr 30, 2026Annual meeting proxy statementFormDEF 14A
- Mar 2, 2026Material agreement entered, material agreement ended, new material financial obligationForm8-K
- Feb 23, 2026Shares registered for employeesFormS-8
- Feb 23, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 18, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Nov 17, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 11, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 3, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 3, 2026 | 8-K | Results of operations | Document |
| Jul 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 21, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Jun 23, 2026 | 8-K | Shareholder vote | Document |
| Jun 16, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| May 22, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 11, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 30, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 30, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 2, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation | Document |
| Feb 23, 2026 | S-8 | Shares registered for employees | Document |
| Feb 23, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 23, 2020.
The full analysis
What do GeneDx's filings show?
The filings are where every one of GeneDx's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.